The following is excerpted from a press release from Baxalta, now a part of Shire. Read the press release in it’s entirety here.

Shire has announced that Vonvendi [von Willebrand factor (Recombinant)], indicated for the on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease, is now available from Shire鈥檚 Hematology Support Center (HSC) through a patient service model.

Patients interested in Vonvendi 聽should speak with their healthcare provider to determine if Vonvendi 聽is right for them.聽 Starting on Vonvendi will require a healthcare provider to enroll the patient in an Activation Program. 聽To learn more about the drug, visit聽

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.